Clinical difference on the variants and co-mutation in a Chinese cohort with ALK-positive advanced non-small cell lung cancer

CONCLUSIONS: In ALK+ NSCLC, longer EML4-ALK variants correlate with improved prognosis and enhanced response to second-generation ALKi, while TP53 co-mutations indicate a negative prognosis.PMID:38637357 | DOI:10.1007/s12094-024-03481-w

Source: Clinical Lung Cancer - April 18, 2024 Category: Cancer & Oncology Authors: Ying Fu Qing Liu Xiaohan Wang Liangchao Sun Xiao Han Xue Meng Source Type: research